The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric Patients

J Pediatr Hematol Oncol. 2017 Jan;39(1):26-32. doi: 10.1097/MPH.0000000000000690.

Abstract

Current practice for selecting donor units for umbilical cord blood transplant (UCBT) involves matching at HLA-A and HLA-B by low-resolution typing and the HLA-DRB1 allele by high-resolution (HR) typing. We retrospectively studied the impact of HR allele matching at HLA-A, HLA-B, HLA-C, and HLA-DRB1 on transplant-related outcomes in 60 single-unit UCBTs in pediatric patients with malignant and nonmalignant conditions. Five-year overall survival of our cohort was 71% (95% confidence interval, 58-81); 27% experienced primary graft failure. Applying HR typing, donor-recipient mismatch variability increased ranging from 1/8 to 8/8, however, no impact on primary graft failure, graft-versus-host disease or posttransplant infection was observed. UCBTs with ≥6/8 HR matches did have a better overall survival (P=0.04) and decreased transplant-related mortality (P=0.02) compared with <6/8 HR matches. Using standard HLA typing, we showed an increased incidence of acute graft-versus-host disease (grade II to IV) and decreased transplant-related mortality in comparing the matched (6/6) versus ≤5/6 group (P=0.05 and 0.05, respectively). These data support the use of current guidelines for umbilical cord blood selection and encourage utilization of HR typing to select umbilical cord blood units matched at ≥6/8 especially when appropriate ≥5/6 units are available.

MeSH terms

  • Acute Disease
  • Adolescent
  • Alleles
  • Child
  • Child, Preschool
  • Cord Blood Stem Cell Transplantation* / adverse effects
  • Cord Blood Stem Cell Transplantation* / mortality
  • Female
  • Genes, MHC Class I
  • Genes, MHC Class II
  • Genetic Diseases, Inborn / therapy
  • Graft Survival
  • Graft vs Host Disease / epidemiology
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / prevention & control
  • HLA Antigens / analysis*
  • HLA Antigens / genetics
  • HLA-DRB1 Chains / analysis*
  • HLA-DRB1 Chains / genetics
  • Hematologic Diseases / therapy
  • Histocompatibility Testing / methods*
  • Humans
  • Infant
  • Infections / epidemiology
  • Infections / etiology
  • Isoantibodies / biosynthesis
  • Kaplan-Meier Estimate
  • Male
  • Neoplasms / mortality
  • Neoplasms / therapy
  • Primary Graft Dysfunction / epidemiology
  • Primary Graft Dysfunction / etiology
  • Primary Graft Dysfunction / prevention & control
  • Recurrence
  • Retrospective Studies
  • Treatment Outcome
  • Virus Activation

Substances

  • HLA Antigens
  • HLA-DRB1 Chains
  • Isoantibodies